💫ASCO #ASCO25 #IMGoncCOP meeting was so genuine, collaborative, and uplifting! 💎With >200 attendees and 20 presenters, we came together to share real experiences, emotional and logistical burdens of moving from abroad, guided the next generation on tackling challenges, and

Finally met my mentor, Dr. Jyoti Malhotra from City of Hope, in person! I am so thankful for her guidance and support as I shape my career!❤️ Jyoti Malhotra City of Hope | Orange County UConn Health #ASCO25

Thank you, Dr. Rami Manochakian, for sharing your insights at the Hematology/Oncology fellowship application roundtable hosted by the ASCO TECAG! The session was incredibly helpful in clarifying many of our questions! #ASCO25 ASCO #MayoClinicFL Mayo Clinic Comprehensive Cancer Center

Just out. Updated myeloma mSMART guidelines on prevention and management of bispecific antibody associated Toxicities. Yi Lin Mayo Myeloma #ASCO25 Comprehensive and covers CRS, neurotoxicity, infection prevention and more. Link: msmart.org/mm-treatment-g…

Key Myeloma therapy update for 2025 1) Newly diagnosed: Start treatment with quads, if possible. (Dara-VRd or Isa-VRd). 2) Auto Transplant: can be deferred for standard risk patients, especially if good response to induction. But collect and store stem cells for future use.

Just out! Latest NCCN guidelines has added daratumumab as Category 1 recommendation for high risk smoldering myeloma. In AQUILA trial, daratumumab: -Delayed progression to active myeloma -Delayed time to needing full myeloma therapy -Better overall survival

Just out: FDA grants accelerated approval to linvoseltamab for treatment of relapsed/refractory myeloma. It is the 3rd BCMA bispecific antibody approved for myeloma. I welcome the choice that patients and physicians have. ajmc.com/view/fda-appro…

[HemOnc fellowship applicant AAMC ID 13775508] I am a resident from UConn (University of Connecticut) pursuing a career in academic Hematology/Oncology. Two years ago, I immigrated from Taiwan to Houston after obtaining a green card based on my research contributions. I have

Advances in Myeloma. 2025 Edition Key takeaways from #IMS25 1) Early intervention is here: Given recent EU approval of daratumumab for high risk smoldering myeloma in Europe, and NCCN category 1 recommendation in the US, ~55% of the attendees would offer early intervention

UNIQLO started selling T-shirt featuring immunotherapy collaborated with Tasuku Honjo, a Nobel laureate for his team's discovery of immune checkpoint, PD-1! As an immuno-oncologist in training, it was an easy decision to purchase this! I do not have COI. uniqlo.com/us/en/products…

Excited to share that our real-world study on bone health in multiple myeloma has received an ASH Abstract Achievement Award and will be presented in a poster session at #ASH25!🩸 🔗 Abstract: submit.hematology.org/program/presen… Grateful to my mentors and collaborators from UConn, Yale,

HISTORIC AND PARADIGM CHANGING: FDA approves daratumumab for high risk smoldering multiple myeloma based on the AQUILA trial— the FIRST ever treatment approved for this indication. Excellent news and thanks to J&J Innovative Medicine and the huge worldwide team of investigators for

Congratulations to Amy Huang on her poster presented at New England Hematology Symposium!

How to follow High Risk Smoldering Myeloma: Observation: If based on shared decision making you choose to follow without therapy this is what I would recommend for newly diagnosed patients: -Every 3 months blood work including M protein and FLC -Annual whole body CT or PET CT